Curis Inc. (CRIS)

2.14
0.08 3.90
NASDAQ : Health Technology
Prev Close 2.06
Open 2.06
Day Low/High 2.05 / 2.15
52 Wk Low/High 0.60 / 2.90
Volume 181.23K
Avg Volume 189.00K
Exchange NASDAQ
Shares Outstanding 33.20M
Market Cap 66.74M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
5 Stocks to Watch Under $5

5 Stocks to Watch Under $5

These under $5 stocks have upside potential.

Curis Announces Collaborator Roche’s Submission Of Marketing Authorization Application For Vismodegib In Advanced Basal Cell Carcinoma

Curis Announces Collaborator Roche’s Submission Of Marketing Authorization Application For Vismodegib In Advanced Basal Cell Carcinoma

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Roche has submitted a...

27 Hot Drugs Facing FDA Approval in 2012

27 Hot Drugs Facing FDA Approval in 2012

These are the biotech and drug stocks facing key FDA drug approval decisions in 2012.

Curis To Present At The Oppenheimer & Company’s 22nd Annual Healthcare Conference

Curis To Present At The Oppenheimer & Company’s 22nd Annual Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at Oppenheimer...

Curis Announces Agreement With The Leukemia & Lymphoma Society To Develop CUDC-907 For Lymphoma And Multiple Myeloma

Curis Announces Agreement With The Leukemia & Lymphoma Society To Develop CUDC-907 For Lymphoma And Multiple Myeloma

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company has entered into an agreement...

Curis To Present At Piper Jaffray 23rd Annual Healthcare Conference

Curis To Present At Piper Jaffray 23rd Annual Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the Piper...

Curis Presents Data On PI3K And HDAC Inhibitor CUDC-907 At The 2011 AACR-NCI-EORTC Symposium

Curis Presents Data On PI3K And HDAC Inhibitor CUDC-907 At The 2011 AACR-NCI-EORTC Symposium

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of data in a poster presentation...

Curis Announces FDA Acceptance And Priority Review Of NDA For Vismodegib As Treatment For Advanced Basal Cell Carcinoma

Curis Announces FDA Acceptance And Priority Review Of NDA For Vismodegib As Treatment For Advanced Basal Cell Carcinoma

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.

Curis Announces Appointment Of Maurizio Voi, M.D. As Chief Medical And Chief Development Officer

Curis Announces Appointment Of Maurizio Voi, M.D. As Chief Medical And Chief Development Officer

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the appointment of Maurizio Voi, M.

Curis To Present At The Lazard Capital Markets Healthcare Conference

Curis To Present At The Lazard Capital Markets Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the Lazard...

Curis Reports Third Quarter 2011 Financial Results

Curis Reports Third Quarter 2011 Financial Results

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the third quarter ended...

Curis To Release Third Quarter 2011 Financial Results And Hold Conference Call On October 27, 2011

Curis To Release Third Quarter 2011 Financial Results And Hold Conference Call On October 27, 2011

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its third quarter financial results on ...

Curis To Present At The 10th Annual BIO Investor Forum

Curis To Present At The 10th Annual BIO Investor Forum

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the 10 th...

Curis To Present At The BioCentury NewsMakers In The Biotech Industry Conference

Curis To Present At The BioCentury NewsMakers In The Biotech Industry Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the...

Curis, Inc. Announces Appointment Of Robert Martell, M.D., Ph.D. To Its Board Of Directors

Curis, Inc. Announces Appointment Of Robert Martell, M.D., Ph.D. To Its Board Of Directors

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the appointment of Robert Martell, M.

Curis Announces Submission Of New Drug Application By Collaborator Genentech For Vismodegib In Advanced Basal Cell Carcinoma

Curis Announces Submission Of New Drug Application By Collaborator Genentech For Vismodegib In Advanced Basal Cell Carcinoma

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the...

Curis To Present At The Rodman & Renshaw 13th Annual Healthcare Conference

Curis To Present At The Rodman & Renshaw 13th Annual Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the Rodman...

Curis Announces Dosing Of First Patient In Phase I CUDC-101 Head And Neck Cancer Combination Trial

Curis Announces Dosing Of First Patient In Phase I CUDC-101 Head And Neck Cancer Combination Trial

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the first patient has been treated in a Phase...

Curis Reports Second Quarter 2011 Financial Results

Curis Reports Second Quarter 2011 Financial Results

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the second quarter ended...

5 Stocks Poised to Break Out

5 Stocks Poised to Break Out

These stocks could be setting up to break out and trade higher from current levels.

Curis To Release Second Quarter 2011 Financial Results And Hold Conference Call On July 28, 2011

Curis To Release Second Quarter 2011 Financial Results And Hold Conference Call On July 28, 2011

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its second quarter financial results on ...

A Busy Week for Six Biotech Stocks

A Busy Week for Six Biotech Stocks

Acura, Pain Therapeutics and Fibrocell deal with FDA approval decisions while Curis presents new cancer drug data.

Curis Announces Presentation Of Positive Vismodegib Pivotal Clinical Data In Advanced Basal Cell Carcinoma

Curis Announces Presentation Of Positive Vismodegib Pivotal Clinical Data In Advanced Basal Cell Carcinoma

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that positive data are being presented by its...

Curis To Present At The Jefferies 2011 Global Healthcare Conference

Curis To Present At The Jefferies 2011 Global Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the...

Curis To Present At The 2nd Annual ThinkEquity Healthcare Conference

Curis To Present At The 2nd Annual ThinkEquity Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the 2 nd...

Curis Inc. Stock Downgraded (CRIS)

Curis Inc. Stock Downgraded (CRIS)

Curis (Nasdaq:CRIS) has been downgraded by TheStreet Ratings from from a hold to sell.

Curis Reports First Quarter 2011 Financial Results

Curis Reports First Quarter 2011 Financial Results

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended...

Curis Reaches New 52-Week High (CRIS)

Curis Reaches New 52-Week High (CRIS)

Curis (Nasdaq:CRIS) hit a new 52-week high Wednesday as it is currently trading at $4.38, above its previous 52-week high of $4.36 with 23,871 shares traded as of 9:31 a.m. ET. Average volume has been 758,700 shares over the past 30 days.

Curis To Release First Quarter 2011 Financial Results And Hold Conference Call On April 28, 2011

Curis To Release First Quarter 2011 Financial Results And Hold Conference Call On April 28, 2011

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its first quarter financial results on ...

Curis To Present At The 18th Annual Future Leaders In the Biotech Industry Conference

Curis To Present At The 18th Annual Future Leaders In the Biotech Industry Conference

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the 18th...

TheStreet Quant Rating: D- (Sell)